TOCA 511 and Toca FC Treatment Misses OS Endpoint in Glioma Trial
Treatment with Toca 511 and Toca FC did not improve overall survival compared with standard therapy in patients with recurrent high-grade glioma undergoing resection, missing the primary endpoint of the phase III Toca 5 trial.
Source: OncLive